HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Bryan F. Meyers Jennifer Bell Zoole Richard J. Battafarano Joel D. Cooper G. Alexander Patterson Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyers, B. F. Articles by Patterson, G. A. Search for Related Content PubMed PubMed Citation Articles by Meyers, B. F. Articles by Patterson, G. A. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2006;131:822-829
© 2006 The American Association for Thoracic Surgery

General Thoracic Surgery

Cost-effectiveness of routine mediastinoscopy in computed tomography– and positron emission tomography–screened patients with stage I lung cancer

^a Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, Missouri.
^b Department of Surgery; the Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri.
^c Siteman Cancer Center, Washington University School of Medicine, Saint Louis, Missouri.

Received for publication April 6, 2005; revisions received September 12, 2005; accepted for publication October 10, 2005.

^_* Address for reprints: Bryan F. Meyers, MD, 3108 Queeny Tower, One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110-1013. (Email: meyersb{at}wustl.edu).

OBJECTIVE: Accurate preoperative staging is essential for the optimal management of patients with lung cancer. An important goal of preoperative staging is to identify mediastinal lymph node metastasis. Computed tomography and positron emission tomography may identify mediastinal lymph node metastasis with sufficient sensitivity to allow omission of mediastinoscopy. This study utilizes our experience with patients with clinical stage I lung cancer to perform a decision analysis addressing whether mediastinoscopy should be performed in clinical stage I lung cancer patients staged by computed tomography and positron emission tomography.

METHODS: We retrospectively reviewed our thoracic surgery database for cases between May 1999 and May 2004. Patients deemed clinical stage I by computed tomography and positron emission tomography were chosen for further study. Individual computed tomography, positron emission tomography, and operative and pathology reports were reviewed. The postresection pathologic staging and long-term survival were recorded. A decision model was created using TreeAgePro software and our observed data for the prevalence of mediastinal lymph node metastases and for the rate of benign nodules. Data reported in the literature were also utilized to complete the decision analysis model. A sensitivity analysis of key variables was performed.

RESULTS: A total of 248 patients with clinical stage I lung tumors were identified. One hundred seventy-eight patients (72%) underwent mediastinoscopy before resection, and 5/178 (3%) showed N2 disease. An additional 9 patients were found to have N2 metastasis in the final resected specimen, resulting in a total of 14/248 patients (5.6%) with occult mediastinal lymph node metastases. Benign nodules were found in 19/248 (8%) of patients. Decision analysis determined that mediastinoscopy added 0.008 years of life expectancy at a cost of $250,989 per life-year gained. The outcome was sensitive to the prevalence of N2 disease in the population and the benefit of induction versus adjuvant therapy for N2 lung cancer. If the prevalence of N2 disease exceeds 10%, the sensitivity analysis predicts that mediastinoscopy would lengthen life at a cost of less than $100,000 per life-year gained.

CONCLUSION: Patients with clinical stage I lung cancer staged by computed tomography and positron emission tomography benefit little from mediastinoscopy. The survival advantage it confers is very small and is dependent on the prevalence of N2 metastasis and the unproven superiority of induction therapy over adjuvant therapy.

This article has been cited by other articles:

				S. A. Defranchi, S. D. Cassivi, F. C. Nichols, M. S. Allen, K. R. Shen, C. Deschamps, and D. A. Wigle N2 disease in T1 non-small cell lung cancer. Ann. Thorac. Surg., September 1, 2009; 88(3): 924 - 928. [Abstract] [Full Text] [PDF]

				G.P. Currie, A.-M. Kennedy, and A.R. Denison Tools used in the diagnosis and staging of lung cancer: what's old and what's new? QJM, July 1, 2009; 102(7): 443 - 448. [Full Text] [PDF]

				B. M. Stiles, E. L. Servais, P. C. Lee, J. L. Port, S. Paul, and N. K. Altorki Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 13 - 19. [Abstract] [Full Text] [PDF]

				S. D. Cassivi, M. S. Allen, G. D. Vanderwaerdt, L. L. Ewoldt, M. E. Cordes, D. A. Wigle, F. C. Nichols, P. C. Pairolero, and C. Deschamps Patient-Centered Quality Indicators for Pulmonary Resection Ann. Thorac. Surg., September 1, 2008; 86(3): 927 - 932. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck Please Lead, But Don't Mislead Chest, September 1, 2008; 134(3): 672 - 672. [Full Text] [PDF]

				A. Watanabe, T. Mishina, S. Ohori, T. Koyanagi, S. Nakashima, T. Mawatari, Y. Kurimoto, and T. Higami Is video-assisted thoracoscopic surgery a feasible approach for clinical N0 and postoperatively pathological N2 non-small cell lung cancer? Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 812 - 818. [Abstract] [Full Text] [PDF]

				B. D. Kozower, B. F. Meyers, C. E. Reed, D. R. Jones, P. A. Decker, and J. B. Putnam Jr Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Ann. Thorac. Surg., April 1, 2008; 85(4): 1166 - 1170. [Abstract] [Full Text] [PDF]

				B. D. Vincent, E. El-Bayoumi, B. Hoffman, P. Doelken, J. DeRosimo, C. Reed, and G. A. Silvestri Real-Time Endobronchial Ultrasound-Guided Transbronchial Lymph Node Aspiration Ann. Thorac. Surg., January 1, 2008; 85(1): 224 - 230. [Abstract] [Full Text] [PDF]

				N. Al-Sarraf, R. Aziz, K. Gately, J. Lucey, L. Wilson, E. McGovern, and V. Young Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 104 - 109. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck, M. A. Jantz, M. Wallace, J. Vansteenkiste, and G. A. Silvestri Invasive Mediastinal Staging of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 202S - 220S. [Abstract] [Full Text] [PDF]

				F. C Detterbeck Evolution and science, progress and change Thorax, August 1, 2007; 62(8): 654 - 655. [Full Text] [PDF]

				P. C. Lee, J. L. Port, R. J. Korst, Y. Liss, D. N. Meherally, and N. K. Altorki Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer Ann. Thorac. Surg., July 1, 2007; 84(1): 177 - 181. [Abstract] [Full Text] [PDF]